Conjugation of statins with drug delivery systems, particularly PLGA nanoparticles, enhances bioavailability and target specificity while decreasing side effects in cardiovascular disease models.
Does the use of polymer nanocarriers for statin delivery improve therapeutic efficacy and reduce side effects in cardiovascular disease?
Polymer nanocarriers, particularly PLGA, represent a promising strategy to enhance the targeted delivery, bioavailability, and efficacy of statins in cardiovascular disease.
Atherosclerosis-related coronary artery disease (CAD) is the leading cause of mortality and morbidity worldwide. This requires effective primary and secondary prevention in reducing the complications related to CAD; the regression or stabilization of the pathology remains the mainstay of treatment. Statins have proved to be the most effective treatment in reducing adverse effects, but there are limitations related to the administration and achievement of effective doses as well as side effects due to the lack of target-related molecular specificity. The implemented technological steps are polymers and nanoparticles for the administration of statins, as it has been seen how the conjugation of drug delivery systems (DDSs) with statins increases bioavailability by circumventing the hepatic-renal filter and increases the related target specificity, enhancing their action and decreasing side effects. Reduction of endothelial dysfunction, reduced intimal hyperplasia, reduced ischemia-reperfusion injury, cardiac regeneration, positive remodeling in the extracellular matrix, reduced neointimal growth, and increased reendothelialization are all drug-related effects of statins enhanced by binding with DDSs. Recent preclinical studies demonstrate how the effect of statins stimulates the differentiation of endogenous cardiac stem cells. Poly-lactic-co-glycolic acid (PLGA) seems to be the most promising DDS as it succeeds more than the others in enhancing the effect of the bound drug. This review intends to summarize the current evidence on polymers and nanoparticles for statin delivery in the field of cardiovascular disease, trying to shed light on this topic and identify new avenues for future studies.
Montelione et al. (Mon,) conducted a review in Atherosclerosis-related coronary artery disease. Polymer nanocarriers for statin therapy was evaluated. Conjugation of statins with drug delivery systems, particularly PLGA nanoparticles, enhances bioavailability and target specificity while decreasing side effects in cardiovascular disease models.